Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Bluebird bio, Inc.    BLUE

BLUEBIRD BIO, INC.

(BLUE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE

11/10/2020 | 09:30pm EST

NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE).  Such investors are advised to contact Robert S. Willoughby at  newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether bluebird and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 4, 2020, bluebird disclosed that the Company will no longer be applying for U.S. Food and Drug Administration ("FDA") approval of its bb1111 product as a treatment for sickle cell disease in the second half of 2021 as expected.  Instead, citing "feedback" from the FDA, "alongside COVID-19 related shifts and contract manufacturing organization COVID-19 impacts, bluebird is adjusting its submission timing to late 2022." 

On this news, bluebird's stock price fell $12.66 per share, or 21.62%, over the following two trading sessions, to close at $45.89 per share on November 6, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com 
888-476-6529 ext. 7980

 

Cision
View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-bluebird-bio-inc---blue-301170451.html

SOURCE Pomerantz LLP


© PRNewswire 2020
All news about BLUEBIRD BIO, INC.
01/11BLUEBIRD BIO : Insiders at Bluebird Bio (BLUE) Make Significant Stock Sales Exte..
MT
01/11BLUEBIRD BIO, INC. : Results of Operations and Financial Condition, Change in Di..
AQ
01/11BLUEBIRD BIO : to spin off cancer drugs unit to focus on genetic diseases
RE
01/11BLUEBIRD BIO : to Separate Oncology Business into Independent Company
BU
01/11BLUEBIRD BIO : to spin off cancer drugs unit - WSJ
RE
01/08INSIDER TRENDS : Insider Adds to Selling Trend at Bluebird Bio
MT
01/08INSIDER TRENDS : Insider Continues 90-Day Selling Trend at Bluebird Bio
MT
01/08INSIDER TRENDS : 90-Day Insider Selling Trend Prolonged at Bluebird Bio
MT
01/08INSIDER TRENDS : Bluebird Bio Insider Continues 90-Day Selling Trend
MT
2020BLUEBIRD BIO, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal ..
AQ
More news